0
0
WASHINGTON (AP) — In a significant move that has sparked debate within public health circles, a top official at the Food and Drug Administration (FDA) has recently overruled government scientists regarding the availability of two COVID-19 vaccines. The decision is part of a broader shift in federal vaccine policy under the current administration, which has already limited routine approval of annual COVID-19 shots for healthy children and younger adults.
Under the new guidelines, annual COVID-19 vaccinations will primarily be available to individuals aged 65 and older, as well as to children and adults with underlying health conditions that increase their risk from the virus. The FDA now requires manufacturers to conduct more extensive studies before modified vaccines can be approved for broader, healthier populations.
This policy shift follows a series of leadership changes and new appointments at federal health agencies. Notably, Dr. Vinay Prasad, a vocal critic of the FDA’s previous handling of COVID-19 booster recommendations, was named the agency’s vaccine chief in May. The FDA also delayed full approval of Novavax’s COVID-19 vaccine and ultimately restricted its use to high-risk groups, a decision that departed from previous federal recommendations advocating annual COVID-19 vaccinations for nearly all Americans over six months old.
The changes have raised concerns among public health experts and vaccine advocates, who warn that restricting access could make it harder for some individuals to receive timely vaccinations and could undermine public confidence in immunization efforts. Some experts have questioned whether pharmacists will be left to decide who qualifies as high-risk and worry that vaccines could become less accessible and less likely to be covered by insurance.
Health Secretary Robert F. Kennedy Jr., who pledged during his confirmation hearings not to undermine vaccinations or impose personal beliefs on federal agencies, has nonetheless overseen unprecedented changes to how vaccines are evaluated, approved, and recommended. While Kennedy stated he would support the CDC’s childhood vaccine schedule and uphold the FDA’s rigorous review standards, his department’s actions have sometimes contradicted established scientific consensus.
The FDA’s new approach has also prompted vaccine manufacturers like Moderna to delay the rollout of new combination vaccines, citing requests for additional effectiveness data from the agency. These developments come as an influential advisory panel to the Centers for Disease Control and Prevention (CDC) prepares to discuss the future of COVID-19 booster recommendations, particularly for children.
“I think you have to assume that RFK Jr.’s intention is to make it harder for vaccines to come to market,” said Dr. Amesh Adalja, a vaccine expert at Johns Hopkins University.
As the debate continues, many in the medical community are closely watching how these policy changes will impact vaccine access and public health outcomes in the months ahead.
Disclaimer: This article is based on information available as of July 4, 2025, and reflects ongoing developments in federal vaccine policy. The situation may evolve as new data and guidance emerge from health authorities.
